Synonym
XVA-143, XV-A143, XVA1-43
IUPAC/Chemical Name
(2S)-2-[[2,6-Dichloro-4-[(3-hydroxyphenyl)methylcarbamoyl]benzoyl]amino]-3-[(3,5-dihydroxybenzoyl)amino]propanoic acid
InChi Key
FZKFBGXSXUYBMX-FQEVSTJZSA-N
InChi Code
InChI=1S/C25H21Cl2N3O8/c26-18-7-14(23(35)28-10-12-2-1-3-15(31)4-12)8-19(27)21(18)24(36)30-20(25(37)38)11-29-22(34)13-5-16(32)9-17(33)6-13/h1-9,20,31-33H,10-11H2,(H,28,35)(H,29,34)(H,30,36)(H,37,38)/t20-/m0/s1
SMILES Code
OC1=CC(C(NC[C@H](NC(C2=C(Cl)C=C(C(NCC3=CC(O)=CC=C3)=O)C=C2Cl)=O)C(O)=O)=O)=CC(O)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
562.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Mancuso RV, Welzenbach K, Steinberger P, Krähenbühl S, Weitz-Schmidt G. Downstream effect profiles discern different mechanisms of integrin αLβ2 inhibition. Biochem Pharmacol. 2016 Nov 1;119:42-55. doi: 10.1016/j.bcp.2016.09.002. Epub 2016 Sep 6. PMID: 27613223.
2: Hajishengallis G, Shakhatreh MA, Wang M, Liang S. Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo. J Immunol. 2007 Aug 15;179(4):2359-67. doi: 10.4049/jimmunol.179.4.2359. PMID: 17675497.
3: Salas A, Shimaoka M, Kogan AN, Harwood C, von Andrian UH, Springer TA. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity. 2004 Apr;20(4):393-406. doi: 10.1016/s1074-7613(04)00082-2. PMID: 15084269.
4: D'Elia R, Jenner DC, Laws TR, Stokes MG, Jackson MC, Essex-Lopresti AE, Atkins HS. Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria. FEMS Immunol Med Microbiol. 2011 Aug;62(3):348-61. doi: 10.1111/j.1574-695X.2011.00817.x. Epub 2011 Jun 16. PMID: 21569124.
5: Parmley LA, Elkins ND, Fini MA, Liu YE, Repine JE, Wright RM. Alpha-4/beta-1 and alpha-L/beta-2 integrins mediate cytokine induced lung leukocyte-epithelial adhesion and injury. Br J Pharmacol. 2007 Nov;152(6):915-29. doi: 10.1038/sj.bjp.0707443. Epub 2007 Sep 10. PMID: 17828290; PMCID: PMC2078224.
6: Wilson ZS, Ahn LB, Serratelli WS, Belley MD, Lomas-Neira J, Sen M, Lefort CT. Activated β2 Integrins Restrict Neutrophil Recruitment during Murine Acute Pseudomonal Pneumonia. Am J Respir Cell Mol Biol. 2017 May;56(5):620-627. doi: 10.1165/rcmb.2016-0215OC. PMID: 28157452; PMCID: PMC5449489.
7: Hajishengallis G, McIntosh ML, Nishiyama SI, Yoshimura F. Mechanism and implications of CXCR4-mediated integrin activation by Porphyromonas gingivalis. Mol Oral Microbiol. 2013 Aug;28(4):239-49. doi: 10.1111/omi.12021. Epub 2013 Jan 21. PMID: 23331495; PMCID: PMC4123224.
8: Xiang X, Lee CY, Li T, Chen W, Lou J, Zhu C. Structural basis and kinetics of force-induced conformational changes of an αA domain-containing integrin. PLoS One. 2011;6(11):e27946. doi: 10.1371/journal.pone.0027946. Epub 2011 Nov 28. PMID: 22140490; PMCID: PMC3225382.
9: Chen W, Lou J, Zhu C. Forcing switch from short- to intermediate- and long- lived states of the alphaA domain generates LFA-1/ICAM-1 catch bonds. J Biol Chem. 2010 Nov 12;285(46):35967-78. doi: 10.1074/jbc.M110.155770. Epub 2010 Sep 6. Erratum in: J Biol Chem. 2011 May 20;286(20):18344. PMID: 20819952; PMCID: PMC2975219.
10: Tardif MR, Gilbert C, Thibault S, Fortin JF, Tremblay MJ. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob Agents Chemother. 2009 Nov;53(11):4656-66. doi: 10.1128/AAC.00117-09. Epub 2009 Aug 31. PMID: 19721069; PMCID: PMC2772324.
